Evotec (EVO) Stock Price, News & Analysis

Company Overview

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design. Its proprietary technologies and automation solutions are engineered to streamline early-stage research, reduce timelines and costs, and improve the probability of success for small molecules, biologics, and cell therapies.

Founded in 1993, Evotec has expanded its capabilities through strategic collaborations, acquisitions, and the growth of its global R&D infrastructure. The company maintains research sites across Europe, North America, and Asia, providing clients with access to diverse scientific expertise and regional innovation hubs in major life sciences clusters.

Evotec’s leadership team brings together seasoned executives from the biotechnology and pharmaceutical industries, guiding a strategic focus on both fee-for-service engagements and milestone-based alliances. Under this direction, Evotec continues to evolve as an integrated drug discovery powerhouse, advancing its own proprietary pipeline alongside its partnership-driven business model.

Key Stats

• Today's Range: $2.76 to $2.83
• 50-Day Range: $2.57 to $3.24
• 52-Week Range: $2.31 to $4.41
• Volume: 13,390 shs
• Average Volume: 100,627 shs
• Market Capitalization: $989.01 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Moderate Buy

Evotec Stock Analysis - MarketRank™

Evotec scored higher than 63% of companies evaluated by MarketBeat, and ranked 262nd out of 849 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Evotec has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Evotec has a consensus price target of $7.00, representing about 152.3% upside from its current price of $2.78.

Amount of Analyst Coverage

Evotec has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Evotec are expected to grow in the coming year, from ($0.63) to ($0.22) per share.

Price to Book Value per Share Ratio

Evotec has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.02% of the float of Evotec has been sold short.

Short Interest Ratio / Days to Cover

Evotec has a short interest ratio ("days to cover") of 2.13, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Evotec has recently decreased by 13.40%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Evotec does not currently pay a dividend.

Dividend Growth

Evotec does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Evotec insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.00% of the stock of Evotec is held by insiders.

Percentage Held by Institutions

5.81% of the stock of Evotec is held by institutions.

Company Calendar

• Last Earnings: 3/31/2026
• Today: 7/10/2026
• Next Earnings (Estimated): 8/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EVO
• CIK: 1412558
• Web: www.evotec.com
• Phone: 49-40-560-81-0
• Fax: 49-40-5608-1222
• Employees: 4,553
• Year Founded: 1993

Price Target and Rating

• Average Price Target for Evotec: $7.00
• High Price Target: $7.00
• Low Price Target: $7.00
• Potential Upside/Downside: +153.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$117.12 million
• Net Margins: -26.20%
• Pretax Margin: -24.26%
• Return on Equity: -24.93%
• Return on Assets: -11.35%

Debt

• Debt-to-Equity Ratio: 0.43
• Current Ratio: 1.68
• Quick Ratio: 1.60

Sales & Book Value

• Annual Sales: $891.97 million
• Price / Sales: 1.10
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.59 per share
• Price / Book: 1.07

Miscellaneous

• Outstanding Shares: 355,760,000
• Free Float: 352,198,000
• Market Cap: $981.90 million
• Optionable: Not Optionable
• Beta: 1.92